Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.44 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22900018 | 0.88 | KIF11 (0.39) | RAPGEF4RAPGEF3KIF11NOTUMAR | |
| SCHEMBL22900078 | 0.88 | KIF11 (0.39) | IDO1RAPGEF4RAPGEF3KIF11AR | |
| SCHEMBL30418237 | 0.85 | CES2 (0.50) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1040760 | 0.85 | CES2 (0.50) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL10610735 | 0.85 | ALDH1A1 (0.43) | KIF11LMNA | |
| SCHEMBL26546127 | 0.84 | IDO1 (0.42) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL12386837 | 0.83 | PDE2A (0.47) | KIF11LMNA | |
| SCHEMBL4792259 | 0.83 | PDE2A (0.51) | RAPGEF4RAPGEF3KIF11NOTUMAR | |
| SCHEMBL5382327 | 0.83 | IDO1 (0.47) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL18768745 | 0.81 | IDO1 (0.44) | IDO1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230330061-A1 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-19 | — | — | US | disclosed |
| US-20230330061-A1 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-19 | — | — | US | disclosed |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-20230286922-A1 | ANTIBIOTIC ADJUVANT COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286922-A1 | ANTIBIOTIC ADJUVANT COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070072859-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286922-A1 | ANTIBIOTIC ADJUVANT COMPOUNDS | MYD88, TLR5, TLR8 | IDO1 2370/4885HTR3E 2671/4885HTR3B 3188/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | IDO1 4374/4885HTR3E 2660/4885HTR3B 1731/4885 |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | IDO1 2076/4885HTR3E 251/4885HTR3B 207/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | IDO1 4374/4885HTR3E 2660/4885HTR3B 1731/4885 |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | IDO1 459/4885HTR3E 544/4885HTR3B 741/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | IDO1 265/4885HTR3E 1503/4885HTR3B 1772/4885 |
| US-20230330061-A1 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | FASN, NAAA, FPR3 | IDO1 899/4885HTR3E 3335/4885HTR3B 3445/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | IDO1 1001/4885HTR3E 3953/4885HTR3B 4436/4885 |
| US-20070072859-A1 | Pharmaceutical compounds | ADRB3, HTR3C, SLC6A2 | IDO1 399/4885HTR3E 61/4885HTR3B 29/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | IDO1 2754/4885HTR3E 3034/4885HTR3B 1935/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | IDO1 2754/4885HTR3E 3034/4885HTR3B 1935/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | IDO1 2823/4885HTR3E 2099/4885HTR3B 1145/4885 |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | LIMK1, LIMK2, ROCK1 | IDO1 1112/4885HTR3E 2272/4885HTR3B 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.